Seer, Inc. (SEER)
Healthcare
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 3
Do Nothing: fundamentalScore 2 and qualitativeScore 2 are below the required floor of 3, and SEER also fails both the $5M average-dollar-volume floor and the $1.5M recent-liquidity floor.
Company overview
Seer, Inc. is a life sciences company focused on developing technologies to explore the proteome's complexities. Its Proteograph Product Suite includes consumables, instruments, and software for advanced proteomic studies. The company serves research applications in academic and biopharmaceutical sectors.
Fundamental
weakSeer has strong liquidity but remains a loss-making entity with high commercialization risk.
Strong liquidity and a large cash/investment cushion reduce near-term solvency risk, but the core business remains loss-making with extreme negative margins and ongoing cash burn. Interim 2026 revenue contracted materially versus the prior year, highlighting adoption and funding-cycle sensitivity even as management reaffirmed modest full‑year revenue guidance. This is best treated as a high-uncertainty commercialization story with runway, not a proven fundamental earnings engine.
Sentiment
weakMedia sentiment is slightly negative, with no clear catalysts to drive positive momentum.
Near-term narrative is dominated by the Aug-11 Q2’26 update (announced) that was broadly read as negative on revenue decline despite reaffirmed full-year outlook, while the earlier unsolicited take-private proposals remain an unresolved strategic backdrop. Media sentiment slipped from slightly positive in the prior 30–90d window (proxy/M&A optionality) to slightly negative over the last ~14d, and the legal screen shows only plaintiff-law-firm solicitation noise (no regulator-confirmed investigation).
Technical
fairThe stock is in a pullback phase, below short-term averages but above long-term support.
SEER still sits above its SMA50 and SMA200 after the late-July expansion, but the stock is below its SMA20 and EMA9/21, RSI14 is 46.78, the MACD histogram is negative, and participation has faded sharply, so the chart reads as a mixed pullback rather than a confirmed bullish swing trigger.
You’re looking at 2026-08-20 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

